Home LiteratureArticle Details
PMID: 23175507 Published · ppublish English Journal Article Review

Pre-existing immunity against vaccine vectors--friend or foe?

Microbiology (Reading, England) ·Vol. 159 ·No. Pt 1 ·2013-01-00 ·Pages 1-11

Saxena M, Van TTH, Baird FJ, Coloe PJ, Smooker PM

Abstract

Over the last century, the successful attenuation of multiple bacterial and viral pathogens has led to an effective, robust and safe form of vaccination. Recently, these vaccines have been evaluated as delivery vectors for heterologous antigens, as a means of simultaneous vaccination against two pathogens. The general consensus from published studies is that these vaccine vectors have the potential to be both safe and efficacious. However, some of the commonly employed vectors, for example Salmonella and adenovirus, often have pre-existing immune responses in the host and this has the potential to modify the subsequent immune response to a vectored antigen. This review examines the literature on this topic, and concludes that for bacterial vectors there can in fact, in some cases, be an enhancement in immunogenicity, typically humoral, while for viral vectors pre-existing immunity is a hindrance for subsequent induction of cell-mediated responses.

MeSH Terms
Animals Bacterial Vaccines/genetics,immunology Drug Carriers Genetic Vectors/immunology Humans Viral Vaccines/genetics,immunology
Chemicals
Bacterial Vaccines Drug Carriers Viral Vaccines
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Saxena Manvendra
Ludwig Institute for Cancer Research, Heidelberg, Victoria, Australia.
Van Thi Thu Hao
School of Applied Sciences, RMIT University, Bundoora, Victoria, Australia.
Baird Fiona J
Comparative Genomics Centre, School of Pharmacy and Molecular Sciences, James Cook University, Townsville, Queensland, Australia.
Coloe Peter J
School of Applied Sciences, RMIT University, Bundoora, Victoria, Australia.
Smooker Peter M
School of Applied Sciences, RMIT University, Bundoora, Victoria, Australia.
References (99)
99 references, click to expand
  1. Recombinant attenuated bacteria for the delivery of subunit vaccines.
    Vaccine. 2001 Mar 21;19(17-19):2621-8 PMID: 11257401
  2. Effect of attenuated Salmonella enterica serovar Typhimurium expressing a Streptococcus mutans antigen on secondary responses to the cloned protein.
    Infect Immun. 2001 Nov;69(11):6604-11 PMID: 11598028
  3. Pre-existing vector immunity does not prevent replication deficient adenovirus from inducing efficient CD8 T-cell memory and recall responses.
    PLoS One. 2012;7(4):e34884 PMID: 22514686
  4. Listeria-based cancer vaccines that segregate immunogenicity from toxicity.
    Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13832-7 PMID: 15365184
  5. Viruses as vaccine vectors for infectious diseases and cancer.
    Nat Rev Microbiol. 2010 Jan;8(1):62-73 PMID: 19966816
  6. T cell responses to Gram-negative intracellular bacterial pathogens: a role for CD8+ T cells in immunity to Salmonella infection and the involvement of MHC class Ib molecules.
    J Immunol. 1999 May 1;162(9):5398-406 PMID: 10228017
  7. Impact of prior immunological exposure on vaccine delivery by Salmonella enterica serovar Typhimurium.
    Vaccine. 2008 Nov 18;26(49):6212-20 PMID: 18852007
  8. Equine viral vaccines: the past, present and future.
    Vet Res. 2004 Jul-Aug;35(4):425-43 PMID: 15236675
  9. Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates.
    J Virol. 2008 Mar;82(6):2975-88 PMID: 18184713
  10. MHC class I antigen processing of Listeria monocytogenes proteins: implications for dominant and subdominant CTL responses.
    Immunol Rev. 1997 Aug;158:129-36 PMID: 9314081
  11. Recombinant Listeria monocytogenes as a live vaccine vehicle and a probe for studying cell-mediated immunity.
    Immunol Rev. 1997 Aug;158:147-57 PMID: 9314083
  12. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
    Nature. 2002 Jan 17;415(6869):331-5 PMID: 11797011
  13. Vectors to achieve selective expression of vaccine antigens within eukaryotic cells using Salmonella spp. as carrier strains.
    FEMS Microbiol Lett. 2000 Jan 15;182(2):219-23 PMID: 10620669
  14. Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines.
    Microb Cell Fact. 2011 Aug 30;10 Suppl 1:S4 PMID: 21995317
  15. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys.
    J Virol. 2008 May;82(10):4844-52 PMID: 18337575
  16. Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A.
    Infect Immun. 1999 May;67(5):2145-52 PMID: 10225867
  17. Long-term immunological memory induced by recombinant oral Salmonella vaccine vectors.
    Infect Immun. 2000 Jul;68(7):4370-3 PMID: 10858264
  18. Rapid protection of gnotobiotic pigs against experimental salmonellosis following induction of polymorphonuclear leukocytes by avirulent Salmonella enterica.
    Infect Immun. 2003 Apr;71(4):2182-91 PMID: 12654840
  19. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.
    Lancet. 2008 Nov 29;372(9653):1894-1905 PMID: 19012957
  20. CD8(+)-T-cell response to secreted and nonsecreted antigens delivered by recombinant Listeria monocytogenes during secondary infection.
    Infect Immun. 2002 Jan;70(1):153-62 PMID: 11748177
  21. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.
    Clin Infect Dis. 2008 Jun 1;46(11):1769-81 PMID: 18433307
  22. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity.
    Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4512-7 PMID: 10200293
  23. Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity.
    J Gen Virol. 2005 Sep;86(Pt 9):2401-2410 PMID: 16099897
  24. Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoelii.
    Vaccine. 2010 Jun 23;28(29):4644-52 PMID: 20451637
  25. Immunogenicity of high expression adenovirus-hepatitis B virus recombinant vaccines in dogs.
    J Gen Virol. 1994 Jan;75 ( Pt 1):125-31 PMID: 8113721
  26. New insights on adenovirus as vaccine vectors.
    Mol Ther. 2009 Aug;17(8):1333-9 PMID: 19513019
  27. IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine.
    Expert Rev Vaccines. 2010 Dec;9(12):1371-84 PMID: 21105774
  28. Effect of preexisting immunity to Salmonella on the immune response to recombinant Salmonella enterica serovar typhimurium expressing a Porphyromonas gingivalis hemagglutinin.
    Infect Immun. 2000 Jun;68(6):3116-20 PMID: 10816452
  29. Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS.
    Hum Vaccin. 2009 Dec;5(12):867-71 PMID: 19786840
  30. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers.
    Vaccine. 2004 Jun 2;22(17-18):2273-7 PMID: 15149786
  31. Pre-existing immunity to pathogenic Listeria monocytogenes does not prevent induction of immune responses to feline immunodeficiency virus by a novel recombinant Listeria monocytogenes vaccine.
    Vaccine. 2005 Feb 10;23(12):1479-90 PMID: 15670884
  32. Salmonella: immune responses and vaccines.
    Vet J. 2001 Mar;161(2):132-64 PMID: 11243685
  33. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.
    J Immunol. 2003 Feb 1;170(3):1416-22 PMID: 12538702
  34. Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans.
    PLoS One. 2011 Apr 13;6(4):e18526 PMID: 21533229
  35. Auxotrophic vaccines for tuberculosis.
    Nat Med. 1996 Mar;2(3):334-7 PMID: 8612234
  36. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon.
    Infect Immun. 2007 Aug;75(8):4105-15 PMID: 17526747
  37. Avipoxviruses: infection biology and their use as vaccine vectors.
    Virol J. 2011 Feb 03;8:49 PMID: 21291547
  38. The potential role of fowlpox virus in rational vaccine design.
    Expert Rev Vaccines. 2006 Aug;5(4):565-77 PMID: 16989636
  39. Attenuated Listeria monocytogenes vaccine vectors expressing influenza A nucleoprotein: preclinical evaluation and oral inoculation of volunteers.
    Microbiol Immunol. 2011 May;55(5):304-17 PMID: 21338384
  40. Immune response to infection with Salmonella typhimurium in mice.
    J Leukoc Biol. 2000 Apr;67(4):457-63 PMID: 10770276
  41. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer.
    Curr Gene Ther. 2008 Apr;8(2):97-120 PMID: 18393831
  42. Vertical and horizontal transmission of salmonella within integrated broiler production system.
    Foodborne Pathog Dis. 2005 Spring;2(1):90-102 PMID: 15992303
  43. Over-expression of major colonization factors of enterotoxigenic Escherichia coli, alone or together, on non-toxigenic E. coli bacteria.
    Vaccine. 2010 Oct 8;28(43):6977-84 PMID: 20728524
  44. Viral vectors in malaria vaccine development.
    Parasite Immunol. 2009 Sep;31(9):501-19 PMID: 19691555
  45. Prior immunity to homologous and heterologous Salmonella serotypes suppresses local and systemic anti-fragment C antibody responses and protection from tetanus toxin in mice immunized with Salmonella strains expressing fragment C.
    Infect Immun. 1999 Aug;67(8):3810-5 PMID: 10417142
  46. Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity.
    J Virol. 2002 Apr;76(8):3678-87 PMID: 11907207
  47. Vector priming reduces the immunogenicity of Salmonella-based vaccines in Nramp1+/+ mice.
    Infect Immun. 2003 Apr;71(4):2258-61 PMID: 12654852
  48. Heterologous prime-boost immunizations with different Salmonella serovars for enhanced antigen-specific CD8 T-cell induction.
    Vaccine. 2008 Mar 28;26(15):1879-86 PMID: 18313813
  49. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization.
    J Virol. 2006 Feb;80(4):1959-64 PMID: 16439551
  50. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
    Nature. 2006 May 11;441(7090):239-43 PMID: 16625206
  51. Emergency and therapeutic vaccination--is stimulating innate immunity an option?
    Res Vet Sci. 2012 Aug;93(1):7-12 PMID: 22015261
  52. Oral delivery of foreign antigens by attenuated Salmonella: consequences of prior exposure to the vector strain.
    Vaccine. 1997 Feb;15(2):155-62 PMID: 9066032
  53. Live oral Salmonella vaccines: potential use of attenuated strains as carriers of heterologous antigens to the immune system.
    Parasite Immunol. 1987 Mar;9(2):151-60 PMID: 3106921
  54. Cross-reactive cellular and humoral immune responses to Salmonella enterica serovars Typhimurium and Enteritidis are associated with protection to heterologous re-challenge.
    Vet Immunol Immunopathol. 2006 Nov 15;114(1-2):84-93 PMID: 16935350
  55. Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28.
    Vaccine. 2010 Aug 9;28(35):5691-702 PMID: 20600496
  56. Recombinant Listeria monocytogenes as a live vaccine vehicle for the induction of protective anti-viral cell-mediated immunity.
    Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3987-91 PMID: 7732018
  57. Listeria monocytogenes. A model system for the molecular study of intracellular parasitism.
    Mol Biol Med. 1989 Oct;6(5):463-74 PMID: 2516599
  58. The induction of HIV Gag-specific CD8+ T cells in the spleen and gut-associated lymphoid tissue by parenteral or mucosal immunization with recombinant Listeria monocytogenes HIV Gag.
    J Immunol. 2003 May 15;170(10):5176-87 PMID: 12734365
  59. Recombinant Salmonella vaccines for biodefence.
    Vaccine. 2006 Apr 5;24(15):2710-7 PMID: 16434131
  60. Induction of a homologous and heterologous invasion-inhibition effect after administration of Salmonella strains to newly hatched chicks.
    Vaccine. 2010 Oct 8;28(43):6958-63 PMID: 20732468
  61. Impact of vector priming on the immunogenicity of recombinant Salmonella vaccines.
    Infect Immun. 2003 Jan;71(1):287-97 PMID: 12496178
  62. Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin.
    PLoS One. 2012;7(2):e31177 PMID: 22363572
  63. Prior immunologic experience potentiates the subsequent antibody response when Salmonella strains are used as vaccine carriers.
    Infect Immun. 1991 Oct;59(10):3841-5 PMID: 1894383
  64. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria.
    Nat Rev Microbiol. 2008 May;6(5):349-62 PMID: 18345021
  65. Impact of preexisting vector-specific immunity on vaccine potency: characterization of listeria monocytogenes-specific humoral and cellular immunity in humans and modeling studies using recombinant vaccines in mice.
    Infect Immun. 2009 Sep;77(9):3958-68 PMID: 19528221
  66. Preexisting immunity to poliovirus does not impair the efficacy of recombinant poliovirus vaccine vectors.
    J Virol. 2001 Jan;75(2):622-7 PMID: 11134275
  67. Construction of non-toxic Escherichia coli and Vibrio cholerae strains expressing high and immunogenic levels of enterotoxigenic E. coli colonization factor I fimbriae.
    Vaccine. 2008 Feb 6;26(6):743-52 PMID: 18191006
  68. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.
    Lancet. 2008 Nov 29;372(9653):1881-1893 PMID: 19012954
  69. Pathogenicity and immunogenicity of a mutant strain of Listeria monocytogenes in the chicken infection model.
    Clin Vaccine Immunol. 2011 Mar;18(3):500-5 PMID: 21228136
  70. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee.
    J Infect Dis. 1992 Oct;166(4):769-75 PMID: 1527411
  71. Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.
    Expert Rev Vaccines. 2009 Apr;8(4):447-54 PMID: 19348560
  72. Viral vectors as vaccine platforms: deployment in sight.
    Curr Opin Immunol. 2011 Jun;23(3):377-82 PMID: 21514130
  73. Comparison of the abilities of different attenuated Salmonella typhimurium strains to elicit humoral immune responses against a heterologous antigen.
    Infect Immun. 1998 Feb;66(2):732-40 PMID: 9453634
  74. Influence of promoter, gene copy number, and preexisting immunity on humoral and cellular responses to a vectored antigen delivered by a Salmonella enterica vaccine.
    Clin Vaccine Immunol. 2009 Jan;16(1):78-87 PMID: 19005022
  75. Poxvirus-vectored vaccines for rabies--a review.
    Vaccine. 2009 Nov 27;27(51):7198-201 PMID: 19925953
  76. Prior exposure to an attenuated Listeria vaccine does not reduce immunogenicity: pre-clinical assessment of the efficacy of a Listeria vaccine in the induction of immune responses against HIV.
    J Immune Based Ther Vaccines. 2011 Jan 18;9:2 PMID: 21244649
  77. Immunity to intracellular bacteria.
    Annu Rev Immunol. 1993;11:129-63 PMID: 8476559
  78. Live attenuated Salmonella: a paradigm of mucosal vaccines.
    Immunol Rev. 1999 Oct;171:5-26 PMID: 10582163
  79. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier.
    J Virol. 2003 Oct;77(20):10780-9 PMID: 14512528
  80. Production of adenovirus vectors and their use as a delivery system for influenza vaccines.
    Expert Opin Biol Ther. 2010 Oct;10(10):1469-87 PMID: 20822477
  81. Expression of two Listeria monocytogenes antigens (P60 and LLO) in Lactococcus lactis and examination for use as live vaccine vectors.
    J Med Microbiol. 2010 Aug;59(Pt 8):904-912 PMID: 20488938
  82. The immune response to a B-cell epitope delivered by Salmonella is enhanced by prior immunological experience.
    Vaccine. 1997 Nov;15(16):1737-40 PMID: 9364676
  83. Attenuated Salmonella typhi and Shigella as live oral vaccines and as live vectors.
    Behring Inst Mitt. 1997 Feb;(98):120-3 PMID: 9382732
  84. Humoral responses and salmonellosis protection in chickens given a vitamin-dependent Salmonella typhimurium mutant.
    Avian Dis. 1991 Jul-Sep;35(3):435-42 PMID: 1953573
  85. In vivo compartmentalization of functionally distinct, rapidly responsive antigen-specific T-cell populations in DNA-immunized or Salmonella enterica serovar Typhimurium-infected mice.
    Infect Immun. 2004 Nov;72(11):6390-400 PMID: 15501769
  86. Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo.
    J Virol. 2009 Jun;83(11):5567-73 PMID: 19279092
  87. Listeria monocytogenes as a vaccine vector: virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy.
    J Immunol. 2004 Jul 1;173(1):420-7 PMID: 15210801
  88. Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer.
    Methods Mol Biol. 2009;542:565-605 PMID: 19565923
  89. Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity.
    Infect Immun. 2005 Oct;73(10):6885-91 PMID: 16177368
  90. Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses.
    J Virol. 2002 Jun;76(11):5565-80 PMID: 11991985
  91. Pre-existing anti-Salmonella vector immunity prevents the development of protective antigen-specific CD8 T-cell frequencies against murine listeriosis.
    Microbes Infect. 2007 Oct;9(12-13):1447-53 PMID: 17913544
  92. Construction of highly attenuated Salmonella enterica serovar Typhimurium live vectors for delivering heterologous antigens by chromosomal integration.
    Microbiol Res. 2008;163(6):605-15 PMID: 19216101
  93. Role of CD4+ T cells and T-independent mechanisms in acquired resistance to Salmonella typhimurium infection.
    J Immunol. 1990 Aug 15;145(4):1265-9 PMID: 1974274
  94. Existing antilisterial immunity does not inhibit the development of a Listeria monocytogenes-specific primary cytotoxic T-lymphocyte response.
    Infect Immun. 1999 Jan;67(1):253-8 PMID: 9864223
  95. Lactococcus lactis expressing either Staphylococcus aureus fibronectin-binding protein A or Listeria monocytogenes internalin A can efficiently internalize and deliver DNA in human epithelial cells.
    Appl Environ Microbiol. 2009 Jul;75(14):4870-8 PMID: 19482952
  96. Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine.
    PLoS One. 2012;7(3):e33428 PMID: 22432020
  97. Strategies to overexpress enterotoxigenic Escherichia coli (ETEC) colonization factors for the construction of oral whole-cell inactivated ETEC vaccine candidates.
    Appl Microbiol Biotechnol. 2012 Mar;93(6):2291-300 PMID: 22350259
  98. Humoral immune response induced by oral administration of S. typhimurium containing a DNA vaccine against porcine reproductive and respiratory syndrome virus.
    Vet Immunol Immunopathol. 2004 Dec 8;102(3):321-8 PMID: 15507315
  99. Noncompetitive expansion of cytotoxic T lymphocytes specific for different antigens during bacterial infection.
    Infect Immun. 1999 Mar;67(3):1303-9 PMID: 10024575
Article Info
Journal
Microbiology (Reading, England)
Abbr.
Microbiology (Reading)
ISSN
1465-2080
DOI
10.1099/mic.0.049601-0
Published
2013-01-00
Epub
2012-00-22
Pages
1-11
Language
English
Region
England
NLM ID
9430468
PMCID
PMC3542731
Subset
IM
External Links
PubMed source DOI: 10.1099/mic.0.049601-0 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2